At the recent American Society of Hematology (ASH) Annual Meeting in San Diego, Dr. David Andorsky, MD, a Clinical Hematologist and Medical Oncologist at the Rocky Mountain Cancer Centers in Boulder, Colorado, presented his research and observations regarding patterns of care with Bruton tyrosine kinase (BTK) inhibitors and the distribution of social determinants of health among patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). In this interview, he further discusses how the treatment landscape of CLL/SLL has changed with the introduction of BTK inhibitors and his next steps for this research.

Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Patterns of Care With BTK Inhibitors for CLL/SLL in the Community Setting: David Andorsky, MD

Oncology Data Advisor®